With 30 years of investing experience, Strong Bio strives to identify highly undervalued biotechnology with clear publically disclosed scientific support in the form of peer reviewed journal articles or data analysis-driven open clinical studies.
Just another guy with a day job and an obsession with the stock market... my goal is to achieve FI (financial independence) sooner rather than later.
My biggest successes have been in the biotech arena (over $300k personal portfolio profits), while my biggest losses have been due to overconfidence and a failure to adequately heed the bear thesis on my picks.
Most of the companies I investigate are growth or turnaround stories.
Important Note for Readers: I'm incredibly thankful for how my investing journey has turned out since first starting in 2008. Although I feel like I'm starting from square one all over again, my past wins have allowed me to buy my penthouse here in Peru, as well as start a clothing chain (with my wife) that I have hopes for. I don't have positions in most of the stocks I write about due to buying the apartment and starting the business. However, at a future time when more funds are available I look forward to having more skin in the game again. In the meantime, I write about stocks as I would approach them, my thesis and game plan- hoping that others find it useful.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Danielle DiMartino Booth makes bold forecasts based on meticulous research and her years of experience in central banking and on Wall Street. Known for sounding an early warning about the housing bubble in the 2000s, Danielle offers a unique perspective to audiences seeking expertise in the financial markets, the economy, and the intersection of central banking and politics.
Macro Investor | Mid/Long Term Horizon | US Equities, Commodities and Fixed Income | English, Dutch & German | Main Goal: Deliver the 1% of Global Data Needed To Make Money | Education | Ask Me Anything: email@example.com |
What to expect from my articles: I write mainly about my basic set of economic indicators that give a solid outlook about the economy. I then discuss trades that fit to the mid/long term outlook.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I participate in Angel Investing and Venture Capital transactions. I have four years of experience in the Capital Markets. This includes, as a Qualified Investor, Angel Investing, Private Equity, Portfolio Management and Equity Trading. I achieved a Bachelors Degree in Business Finance at the University of Northern Colorado.
My preferred method of contact is via email at: firstname.lastname@example.org
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
I worked almost 30 years in the pharmaceutical industry. I started as a sales rep after earning my degree in biological sciences and (later) biomedical sciences. I then went back to school, got my MBA, and spent the following 20 years working up the ranks. I spent the latter parts of my career working as an analyst, meaning I would analyze data on 1,000s of compounds, collect reports from scientists, and then present the information to those who decided whether the candidates would go on to clinical trials (additional preclinical studies) or would be thrown to the dumpster for some small company to find and develop further. I have worked in just about every department in the pharmaceutical industry, including biotechnology, oncology, infectious disease, genetics, etc.
Now that I am recently retired, I have joined Seeking Alpha to share my knowledge of the healthcare industry, and discuss trends that I've seen throughout my career. I have chosen the task of managing my own retirement accounts, therefore Seeking Alpha has become a great interest to me.
I am hoping to learn and teach via Seeking Alpha. Also, my grandchildren call me Shennie so that's what I go by these days
I run an equity research training program with a focus on the practical application of financial modeling, company and industry analysis.
Visit www.quadrantskewcapital.com for more details
Contact me at email@example.com
I am an accountant by profession but as a finance student have always taken a keen interest in the financial markets. Through Seeking Alpha I want to earn, and also, educate myself on the latest trends and methods of financial investing.
Travis is a 4.5-star expert per TipRanks. He primarily invests in smid-cap stocks for long term positions, but partakes in some event driven activity: IPO, biotech run-ups, etc. As an investor, he is looking for value stocks that Mr. Market has overlooked (J.Greenblatt).
With a professional background from public school teaching to government investigation; he utilizes a multifaceted writing and research discipline. Prefers FinViz stock screener.
Twitter: DIY_S_Investor StockTwits: DIY_Stock_Investor Website: DIY Stock Investor
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
I am a dividend investor and look for undervalued investments in the stock market. I identify misunderstood and undervalued equity investments and hold those securities until their price approximates my estimate of intrinsic value. I am a long-term investor only.
I am building a $100,000 high-yield income portfolio. I am running this portfolio as an experiment to see if long-term sustainable income can be generated from a diversified pool of high-risk, high-yield securities. I am willing to accept high risk in order to meet my performance goals.
Leigh Drogen is the Founder and CEO of Estimize.com and Forcerank.com. Estimize is an open financial estimates platform which facilitates the aggregation of fundamental estimates from independent, buy-side, and sell-side analysts, along with those of industry experts and private investors. By sourcing estimates from a diverse community of individuals, Estimize provides both a more accurate and more representative view of expectations compared to sell side only data. Leigh started his career as a quant trader at Geller Capital, a White Plains, NY based fund where he ran strategies that looked at earnings acceleration and analyst estimate revision models, as well as price momentum and several sentiment indicators. Leigh later went on to be the founder of Surfview Capital, a New York based asset management firm that used many of the same strategies as Geller Capital, with a focus on higher beta names on an intermediate term time frame. His educational background includes focus in economics and international relations, specifically war theory. He is a graduate with honors from Hunter College in New York City. You can contact Leigh by emailing him at Leigh@estimize.com
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Renaissance Capital is an IPO investment advisory firm providing pre-IPO institutional research and management of IPO-focused funds including the Renaissance IPO ETF (NYSE ticker: IPO), the Renaissance International IPO ETF (NYSE ticker: IPOS) and the Global IPO Mutual Fund (ticker: IPOSX). Through Renaissance Capital’s pre-IPO research service, investors get a hard-nosed, independent opinion, in-depth fundamental analysis and customizable financial models on all IPOs. The Firm's clients also gain access to the premier IPO knowledge base with deal calendars, market commentary, fundamental data on over 5,000 past IPOs and more.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
Bachar Samawi is Founder of Bachar Samawi Ventures (http://www.samawi.net).
Bachar Samawi has 29-years international experience in finance, trading, new business development, private equity and investment management, spanning multiple sectors including Banking, Energy, Technology, Agro, Industry, Healthcare and Real Estate.
As Chief investment Officer for one of Qatar Holding’s international $5 Billion subsidiary partnerships (Qatar Holding / Qatar Investment Authority is the $250 Billion Qatar Sovereign Wealth Fund), Mr. Samawi was primarily responsible for evaluating and determining investment opportunities (which include Healthcare, Banking, Energy, Agriculture, and other), as well as launching projects with expected private equity requirement in excess of $100 Million per project. To such effect, Mr. Samawi deployed his Wall Street experience to lead meetings and negotiations with all stakeholders, including government officials and ministers, major banks, investors, financiers, international organizations, global corporations, diplomatic missions, and more.
As Vice Chairman of the Board of Directors and Managing Partner for Caltech Developments Limited - Your Global Partner in Energy, Mr. Samawi led strategy & structuring on multi-billion dollar long-term crude oil refining supply negotiations.
Mr. Samawi held senior level positions with multi-Billion dollar institutions in the USA and the Middle East including National Energy Group in the Washington DC area (non-regulated subsidiary of $18 Billion Pacific Gas & Electric), where he built the power trading department, Sanwa-BGK in New York (US Primary Dealership subsidiary of Sanwa Bank, which later merged with Tokai Bank and Mitsubishi Tokyo Financial Group, to become today’s $75 Billion Mitsubishi UFJ Financial Group), where he co-founded the Fixed Income OTC Options department, and other international holding companies (diversified in Banking, Industry, Real Estate, Services and Trade).
His responsibilities included launching new businesses, setting up departments generating income in excess of $100 Million annually, negotiating and securing partnerships with Top Five international conglomerates in Energy and Finance, advising Board of Directors on Strategic Ventures, acting as Interim CEO, trouble-shooting and turning around struggling businesses, optimizing financial and real estate portfolios, and more.
Samawi graduated from Yale University with a double major in Computer Science and Economics. He has also completed numerous certifications in Finance and Management & Leadership training and is fluent in English, French and Arabic. Samawi has also authored numerous articles and white papers, and has given speeches throughout the world including France, Germany and the USA.
I provide stock and bond analysis to a small cap specialist investor. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the equity research company "BNL Finance". An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Hunter graduated with a Bachelors in Economics from the University of South Florida. He followed up with a Master's in Finance from the University of Tampa. During those years he earned the Chartered Financial Analyst (CFA) designation.
Alpha Street Research is a leading and award winning equity research firm. Our unbiased actionable and quantitative research helps investors identify individual equity opportunities and marco market opinions.
visit the site www.AlphaStreetResearch.com to learn more about the audited performance of the Alpha Street Research ranking system.
Harry Long is the inventor of Hedged Contango Capture and Hedged Convexity Capture and is the Managing Partner of ZOMMA, the world's most innovative strategy index creator.
Mr. Long is a globally recognized expert on the research and development of quantitative investment strategies. The ZOMMA IP portfolio of strategy indices is sought after by asset management firms, investment banks, hedge funds, principal trading organizations, index providers, ETP sponsors, and private equity firms to help them develop and deploy active manager-crushing quantitative investment strategies.
ZOMMA helps investors create long term value by replacing reckless emotional decision making with cutting-edge technology based upon objective evidence.
Mr. Long is a graduate of Rice University with a B.A. in Economics.
Note: Due to the sheer number of requests for bespoke quant strategies, research projects, and quant consulting services, we have instituted the following pricing for the non-exclusive licensing of our algorithms to institutions:
I. Exclusive commercial licenses for unique bespoke algorithms run six figures and up.
II. Non-exclusive AUM licensing fees for our strategy indices run 10 basis points and up for commercial licenses.
Please realize that we often get more than 3,000 e-mails per week. This means that we read everything that comes in, but we cannot respond to any email or message that does not include the sender's full name, phone number, request, and budget. Thank you for your understanding.
This Dubai-like pricing is necessary, because we can't freely give answers to tough problems which we have dedicated massive R&D capital to solving. World-class statistical talent is hugely expensive, valuable, and rare. Our clients recognize that outsourcing quant work to our firm and paying our fees represent a huge cost savings over hiring full time employees, and usually results in a far more profitable, turn-key solution.
Simple qualitative analysis is a key component of every investment thesis. I am particularly good at keeping it simple and to the point. My analysis focuses on finding undervalued opportunity in growth industries. I am a long term investor working to buy great companies with a great story at a great price.